Japan Avarept 0.3% Suspension Eye Drops: Dry Eye Treatment—Restores Moisture and Reduces Inflammation

1
SKU: N/A
HKD$780.00 Original price was: HKD$780.00.HKD$690.00Current price is: HKD$690.00.
In Stock
WhatsApp Product Inquiry
Add to wishlist
Compare
Free shipping on orders over HKD $500, USD $200, or CNY ¥500.
Delivery within 4–7 business days.
Money Back Guarantee
No shipping on Sat, Sun & Japanese national holidays.

描述

Direct overseas shipping (Direct shipping from Japan)

Abarept Suspension Eye Drops 0.31 TP3T
AVAREPT Ophthalmic Suspension 0.3%

YJ Code 1319767Q1020 | Approval Number 30700AMX00260
Prepared in December 2025 (1st Edition)

Dry Eye Treatment | TRPV1 Antagonist | Avarept | Eye Drops

Avarelput Suspension Eye Drops

Product Details / Approval Status, etc.

Japan Standard Commodity Classification Code 871319
Pharmacological Classification Name Dry Eye Treatment (TRPV1 Antagonist)
General Name Abarept
Motugivatrep
Product Name Abarept Suspension Eye Drops 0.31 TP3T
AVAREPT Ophthalmic Suspension 0.3%
YJ Code 1319767Q1020
Approval Number 30700AMX00260
Sales Begin April 2026
Storage Instructions / Expiration Date Store upright at room temperature / 3 years
Regulatory Classification Prescription Medications
Manufacturing and Sales Yuan Qianshou Pharmaceutical Co., Ltd.
1-9 Kawara-machi 3-chome, Chuo Ward, Osaka City
Sale Takeda Pharmaceutical Co., Ltd.
Packaging Plastic Eye Drop Containers, 5 mL × 10, 5 mL × 50

1. Product hint

Approval Conditions: A drug risk management plan must be developed and properly implemented.

This is a new drug; until March 31, 2027, administration is limited to 14 days per dose.

2. Product Characteristics and Mechanism of Action (18.)

Abalept is believed to improve the subjective symptoms and objective findings associated with dry eye syndrome by inhibiting TRPV1 in trigeminal ganglion cells, corneal epithelial cells, and T cells. It exhibits potent inhibitory activity against TRPV1 in both humans and rats.

3. Specifications and Properties (3.2)

When shaken, this is a white, sterile, aqueous suspension for ophthalmic use. pH 7.2–7.7. Osmolarity (ratio relative to normal saline) 0.9–1.1.

4. Ingredient Information (3.1/19.)

3.1 3 mg of Abalept per 1 mL.

Excipients: Tylosap, methylcellulose, boric acid, zinc chloride, borax.

19. Chemical name: (2E)-N-[(7R)-7-Hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]-2-[7-(trifluoromethyl)-2, 3-dihydro-4H-1-benzopyran-4-ylidene]acetamide. Molecular formula C22H20F3NO3. Molecular weight 403.39. White powder. Melting point approximately 234°C.

5. Indications and Usage (4.)

Dry Eye Syndrome

6. Dosage and Administration (6./14.)

Usually, instill 1 drop into each eye 4 times a day.

14. Precautions for Use

  • Before use, shake the bottle well while keeping the cap closed, then open the cap and apply the drops to your eyes.
  • To prevent contamination of the solution, be careful not to let the tip of the container come into direct contact with your eye when applying the eye drops.
  • Open the affected eye, instill the eye drops into the conjunctival sac, close your eye for 1 to 5 minutes while applying pressure to the lacrimal sac, and then open your eye again.
  • If using other eye drops, wait at least 5 minutes before applying this product.
  • Depending on how this product is stored, the particles may not disperse even when shaken; therefore, please store it upright until you are ready to open it.

7. Important Notes (8./9./11.)

8. Important Basic Precautions After instilling the eye drops, temporary blurred vision may occur; therefore, please exercise caution when operating machinery or driving. Depending on the plasma concentration of the TRPV1 antagonist, it may cause temperature-related abnormalities, including an increase in body temperature—potentially severe fever—and an elevated thermal pain threshold. Particular attention should be paid to the risk-benefit balance, especially in patients with low body weight, including children. Due to an elevated thermal pain threshold, patients may fail to detect heat sources, potentially leading to burns, including low-temperature burns.

9. Patients with specific medical histories Patients with hepatic impairment: Pharmacokinetics have not been studied. Pregnant women: Administer only if the therapeutic benefits are deemed to outweigh the risks. Breastfeeding women: Consider whether to continue or discontinue breastfeeding. Children, etc.: No clinical trials have been conducted. Elderly patients: Physiological functions, etc., may be reduced.

11.2 Other Side Effects Eyes: Cold sensation in the eyes, blurred vision (1–51 TP3T or less); allergic conjunctivitis, corneal erosion, itchy eyes, abnormal sensation in the eyes, foreign body sensation, discomfort, increased tearing (0.1–11 TP3T), sensation of heat in the eyes (frequency unknown). Other: sensation of cold (1–51 TP3T), diminished temperature sensation, elevated body temperature, sensation of heat, abnormal sensations, hot flashes (frequency unknown).

8. Contraindications (2.)

Patients with a history of allergic reactions to any of the ingredients in this medication

17. Clinical Results (for reference)

Domestic Phase III Comparative Trial: 536 patients with dry eye syndrome; placebo-controlled. After 4 weeks of treatment, the superiority of this treatment group over the placebo group was demonstrated in terms of the change from baseline in the total DEQS score (difference −2.40, p=0.0433). The main adverse effects in this treatment group were a sensation of cold, a sensation of cold in the eyes, and blurred vision.

※ This page is compiled from information in the package insert and is not a substitute for a doctor’s prescription or the original Japanese version. For details, please refer to the PMDA package insert.

[Disclaimer]

  1. The information regarding medications, treatments, or health management contained in this article is compiled from international authoritative medical journals and official clinical literature, and is intended for general science and educational reference only.
  2. The indications, side effects, and contraindications of related medications may vary depending on national regulations and individual physical conditions. Do not blindly take medication on your own or change your treatment plan.
  3. The author and publishing platform assume no legal liability for any medical delays, adverse reactions, or direct or indirect losses caused by the use of the information in this article. All medical decisions should be discussed with your attending physician before being made.

Additional information

Specifications

Avarept 0.3% Eye Drops

1 review for 日本 Avarept アバレプト0.3% 懸濁性點眼液 干眼治療跳出補水抗炎

5.00

Average of 1 review

  1. HK –

    Good

Add a review

Your email address will not be published. 必填欄位標示為 *

Recently viewed

Add to wishlist
5.00

Japan WAKAMOTO Strong Wakamoto Stomach-Strengthening and Intestinal-Cleansing Pills: 1,000 tablets

HKD$156.00
Select options This product has multiple variants. The options may be chosen on the product page
Add to wishlist
Store
Search
Wishes
cart
Track
Account
Select currency

No products in the cart.

Copyright 2026 © Hkeemall. All rights reserved. |  Return and Exchange Policy  |  Privacy Policy  |  Contact us